Treatment with a preparation of monophosphoryl lipid A, known to be capable of abolishing the expression of CD8+ suppressor T cell activity generated during the antibody response to type III pneumococcal polysaccharide (SSS-III), was found to have no adverse effect upon either induction or expression of CD8+ cytotoxic T lymphocyte activity specific for influenza A virus antigens. This suggests that suppressor T cells and cytotoxic T lymphocytes represent functionally distinct subsets of CD8+ T cells which can be differentiated on the basis of their sensitivities to inactivation by monophosphoryl lipid A.
Recent studies showed that treatment with bacterial monophosphoryl lipid A (MPL) abrogates the expression, but not the induction, of the activity of CD8+ suppressor T cells (Ts) elicited in response to type III pneumococcal polysaccharide (SSS-III) (8, 9) . This occurs without adversely influencing functions mediated by CD4+ amplifier T cells (Ta) (8, 9) and helper T cells (Th) (8) . It results in the reversal of low-dose immunological paralysis, a form of antigen-specific unresponsiveness mediated by CD8+ Ts (5, 6, 30) , and enables Ta activity to be more fully expressed, as evidenced by an increased antibody response to SSS-Ill (8, 9) . Prior in vitro treatment with MPL also abolishes the capacity of spleen cell suspensions containing Ts activity to transfer suppression to recipient mice immunized with SSS-III (15, 19) . These observations imply that Ts, once activated, acquire a cell surface receptor for MPL and/or possess a biochemical pathway that is sensitive to being blocked or inactivated by MPL (5, 8, 19) . MPL, therefore, can be considered to be a potent immunomodulator, since by eliminating the inhibitory effects of Ts it can greatly increase the expression of an immune response.
In the present work, the effect of in vitro and in vivo treatment with MPL on both the induction and expression of the activity of influenza virus-specific CD8+ cytotoxic T lymphocytes (Tc) was examined to determine whether the aforementioned effects of MPL are selective for Ts (29, 31) .
Generation of Tc. Tc were generated in vitro as described previously (32) . Briefly, spleen cell suspensions were prepared from mice inoculated at least 2 weeks earlier with 200 HAU of PR/8/34 virus. Then, 2 x 106 cells per ml were restimulated with either NP peptide (1 ,ug/ml) or syngeneic spleen cells infected with PR/8/34 (106 cells per ml) for 7 days. It should be noted that stimulation with NP peptide induces exclusively anti-NP-specific Tc, whereas stimulation with virus-infected cells results in the development of several populations of Tc recognizing different viral proteins, including NP (3).
Preparation of target cells for use in cytotoxicity assays. Target cells were infected with PR/8/34 and labeled with 51Cr as described previously (32) . Chromium-labeled target cells were sensitized with NP peptide for use in cytotoxicity assays by adding to the cultures 10 p.l of tissue culture medium containing peptide, giving a final peptide concentration of 10-6 M. Peptide was present in culture throughout the cytotoxicity assay to generate a secondary cytotoxic response directed against the epitope of that peptide.
Cytotoxicity assay. Tc generated after 7 days of culture were washed and then resuspended in Iscove's Dulbecco's modified Eagle's medium supplemented with glutamine (100 mM), gentamicin (50 ,ug/ml), P-mercaptoethanol (5 x 10-' M), and 7.5% heat inactivated fetal bovine serum (3, 32 (29) recognize NP peptides 147-158 and 365-380; also, it has been established that the secondary cytotoxic response generated after exposure to these peptides is epitope specific as well as class I restricted (3, 32) .
RESULTS
Effect of treatment with MPL(SM) on the expression of Ts activity involved in the antibody response. BALB/cByJ mice were pretreated (primed) with a single injection (i.p.) of a subimmunogenic dose (5 ng) of SSS-III; 3 days later, they were immunized (i.p.) with an optimal dose (0.5 ,ug) of SSS-III, and the magnitude of the antibody (SSS-Ill-specific PFC) response produced was determined 5 days after immunization. The results obtained were compared with those of unprimed immunized controls.
Priming with S ng of SSS-Ill resulted in the development of significant (P < 0.001) immunological unresponsiveness, as expected (Table 1) ; it has been established that such unresponsiveness is antigen specific, persists for several weeks to months after priming with a single injection of SSS-III, and is mediated by CD8+ T cells that become fully activated 3 days after priming (5, 6, 30) . If primed mice are given (i.p.) 25 ,ug of MPL(SM) with 0.5 ,ug of SSS-III on the day of immunization (day 0) and one day after immunization (day +1), unresponsiveness is abolished; i.e., the resulting response does not differ from that of unprimed immunized controls (P > 0.05; Table 1 ).
The ability to transfer antigen-specific low-dose paralysis with CD8+ T cells (6, 30) attests to the fact that such unresponsiveness is mediated by Ts and enables one to examine directly the ability of MPL(SM) to abolish Ts activity by using a preparation of MPL derived from S. typhimurium [MPL(ST)], as described in another study (15) .
The in vitro treatment of primed spleen cells with extremely small amounts (5 pg, 5 ng, or 5 jig) of MPL(SM) abolished their ability to transfer suppression to recipient mice immunized with SSS-Ill (19) . All of these findings are in complete accord with those obtained in previous studies (8, 15, 19) conducted with MPL(ST). Therefore, the inactivation of Ts activity is a general property of MPL The data of Fig. 2 show that treatment with two injections of MPL(SM) during the first 7 days after inoculation with virus had no discernible effect on the induction of Tc activity; however, treatment with four injections of MPL(SM), two during the first week and two during the second week after inoculation with virus, resulted in a marked increase in the degree of Tc activity generated. The increase was most pronounced with target cells sensitized with NP peptide 147-158, although it also was apparent with target cells infected with PR/8/34. The specificity of cytotoxicity was affirmed by the fact that no 5tCr release was noted and antigen-specific manner to influence the magnitude of the antibody response to SSS-III (4, 5, 10), the major differences between Ts and Tc, which likewise are CD8+ (4) and are generated during the immune response to viral antigens and alloantigens, remain to be more fully defined. The ability of either T cell depleting agents or the infusion of cell suspensions possessing CD4+ Ta activity to reverse the inhibitory effects of Ts in vivo indicates that Ts activated during the immune response to SSS-Ill are regulatory rather than cytotoxic in their mode of action (reviewed in reference 7). Because of these and other observations, it has been proposed that the magnitude of the antibody response to SSS-III is controlled by two types of regulatory T cells (Ts and Ta) that act in an opposing and competitive manner on B cells to limit the extent to which antigen-stimulated B cells proliferate after immunization (reviewed in references 4, 5, and 10). All experimental data acquired to date are in accord with such a homeostatic model for regulating the magnitude of the antibody response. Fitch et al. (21) reported that the ability of irradiated spleen cells from mixed leukocyte cultures (MLC) to inhibit the generation of Tc activity is due mainly to the inactivation of alloantigen-bearing stimulator cells by residual Tc present in the irradiated cell suspensions used; this results in a marked decrease in the degree of Tc activity generated when such cells were added at the initiation of MLC. Here, both the suppression noted and the cytotoxic activity expressed are considered to be mediated by the same population of T cells acting under different experimental circumstances. By contrast, the work of Al-Adra and Pilarski (1) provided convincing evidence to indicate that the suppression induced during primary (first-step) MLC reactions is not mediated by Tc. Rather, it is the result of a distinct regulatory process engendered by the ability of both responder and inhibitory cells (Tc and Ts, respectively) to recognize and respond to the same alloantigens on the surface of stimulator cells. The capacity of cyclosporin A to block the activation of Tc, but not the generation of noncytolytic alloantigen-specific Ts, affirms that suppression and cytotoxicity are mediated by separate populations of T cells (16) . Also, the ability to induce alloantigen-specific Ts activity in the absence of Tc activity (28) , as well as the ability to differentiate between Ts and Tc on the basis of CD11b and CD28 phenotype (25) or sensitivity to inactivation by monoclonal antibodies specific for antigen-specific suppressor factors (18) , provides additional support for the view that Ts indeed represent a separate subset of CD8+ T cells.
In the present work, treatment with a preparation of MPL known to abolish the expression of CD8+ Ts activity involved in the antibody response to SSS-III (Table 1 ) (11) had no adverse effect on either the in vitro expression (Fig. 1) or the in vivo induction (Fig. 2 ) of CD8+ Tc activity specific for viral antigen. This indicates that Ts and Tc represent functionally distinct subsets of CD8+ T cells which can be differentiated on the basis of their sensitivity to inactivation by MPL. The ability of MPL to increase the frequency or degree of Tc activity expressed (Fig. 2) provides additional support for such a view; it shows that MPL, presumably by eliminating the inhibitory effects of Ts known to be generated during the course of cytotoxic immune responses (1, 16-18, 25, 28) , permits the effects produced by Tc to be more fully expressed.
The results of the present work (Fig. 2) indicate that little or no MPL-sensitive suppression is evident during the first week after the inoculation of virus; however, such suppression appears to be expressed during the second week after virus infection, as evidenced by an increase in the degree of Tc activity expressed in mice given four injections of MPL. The ability of MPL to increase the degree of Tc activity generated during the primary (Fig. 2) , but not the secondary (Fig. 1) , response to viral antigens suggests that such suppression may have a decisive effect during the initial stage of clonal expansion of Tc. Also, since previous studies (8, 9) showed that MPL acts mainly on activated rather than resting or precursor Ts, it is conceivable that greater increases in Tc activity might be achieved by giving the same or larger doses of MPL at different times after exposure to viral antigens. Clearly, more detailed and systematic studies which are beyond the scope of the present work are required to establish the experimental conditions for maximizing the effects of MPL for this immune response.
The ability of MPL to abrogate the expression of Ts activity, without adversely influencing the expression of Tc as well as other T cell functions (8, 9) , has profound implications with respect to increasing the development of T cell-mediated immunity. There is much evidence to indicate that Ts activity is generated not only during the course of a normal antibody response (5) but also during UV radiationinduced carcinogenesis (20) and during the immune response to tumor antigens (24, 26, 27) ; in the latter case, the development of Ts activity, albeit of different antigenic phenotype, has been shown to inhibit the regression of tumor growth mediated by Tc. Obviously, under such conditions, MPL might be used with great advantage to promote or increase the efficiency of tumor immunity. This is being investigated in collaborative studies with other investigators.
